Home » Expert Content » Drug Substance Manufacturing

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

BROWSE BY

TOPIC:






TYPE:





Complex Protein Production

Summary: Download the eBook to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture medium and feed to maximize…

read more

Biomanufacturing Infocard

Summary: Catalent Biologics’ two state-of-the-art facilities have been designed to provide integrated bulk drug substance for clinical trials and commercial launches.

read more

Continuous Processing In Biomanufacturing

Summary: As the biologics industry continues to grow, biopharmaceutical companies are evaluating continuous processing as a potential means to improve efficiencies. There are many factors to consider when determining whether continuous processing should be adopted, and if so, what adoption strategy should be used…

read more

The Next Step In Homogeneous Bioconjugate Development

Summary: Bringing a new biologic drug to the market is a long and expensive process with R&D cycles that can span more than 15 years and cost over a billion dollars. Nonetheless the pharma industry is increasingly shifting efforts to focus on these types of compounds…

read more

ADC Development Using SMARTag™ Technology

Summary: Bioconjugates are an emerging class of biologics that combine the favorable properties of proteins, such as specificity and the ability to target distinct protein interfaces, with the advantages of synthetic small molecules, such as potency, bioavailability, and synthetic tractability. Early examples of bioconjugates include proteins linked to…

read more

Designing Optimized, Site-Specific ADCs

Summary: Antibody-drug conjugates have provided a breakthrough in targeted medicines but ways of increasing their stability and efficacy are still required. Historically, the technologies used to build these two approved products result in a heterogeneous milieu of conjugates…

read more

Viral Clearance For Biopharmaceutical Downstream Processes

Summary: Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals. These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses. This paper reviews regulatory guidance and practical strategies for designing viral clearance studies…

read more

Generating Aldehyde-Tagged Antibodies

Summary: This article is a selection of articles published in BioMed Central Ltd., giving overview on the ability to site-specifically conjugate a protein to a payload of interest has found widespread application in basic research and drug development…

read more

New Ideas For Antibody-Drug Conjugate Design

Summary: This article is a selection of articles published in The Scientist, giving overviews on new ideas for antibody-drug conjugates designs so oncologists can aim a chemical payload at any cell for which they can identify a specific antigen, such as the HER2 receptor on breast cancer cells…

read more

Novel Analytical Techniques For Monoclonal Antibodies

Summary: With the rising interest in biopharmaceuticals, drug developers need to quickly understand and evaluate the binding of therapeutic antibodies to Fc receptors. In this interview with Pharmaceutical Technology, Michael Sadick, Ph.D., and Dan Papa, Ph.D., of Catalent Biologics, talk about a new analytical testing panel…

read more

Biopharma Manufacturing Trends

Summary: As pharma companies look more and more to biologics for their next potential blockbusters, they must face the challenges surrounding these products’ scientific complexity and sophisticated development…

read more

Antibody-Drug Conjugates – Where Are We Now?

Summary: In October 2015, during CPhI World Wide in Madrid, Spain, Oncology Tube from InPress Media Group, LLC. asked experts from Piramal Pharma Solutions, Carbogen Amcis and Catalent Biologics about challenges in the manufacturing of ADCs and how they see the market for ADCs evolve…

read more

The Ever-increasing Attraction of Biologics

Summary: The field of biologics promises targeted treatments for a range of conditions. For the promise of many of these therapies to become a reality, however, technological challenges must still be overcome, with many exciting novel treatments currently on, or making their way to, the market. This article published in Chemistry World discusses…

read more

Moving A Complex Protein From Development To Large-Scale Clinical Production

Summary: The number of more complex biopharmaceuticals in development continues to increase. These include molecules like virus-like particle vaccines, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, and more recently, numerous different multi-specific antibody platforms…

read more

Single-Use Bioreactors Pose E&L Challenges

Summary: Read the recent roundtable Q&A published in BioPharm International featuring biopharma executives discussing the challenges posed by single-use bioreactor bags in contributing to extractables and leachables in the biomanufacturing process…

read more

Accelerating Biologics And Biosimilar Development

Summary: Get to know how Catalent’s scientists have utilized ambr 15® as a micro-scale model for a synergistic clonal and process screen to identify the master cell bank candidates. Using this multi-layered approach, early in the development process significantly improves selection of top clones while shortening the overall timeline…

read more